Αποτελέσματα Αναζήτησης
Sharing Alzheimer’s research data with the world. The Alzheimer’s Disease Neuroimaging Initiative (ADNI) is a longitudinal, multi-center, observational study. The overall goal of ADNI is to validate biomarkers for Alzheimer’s disease (AD) clinical trials.
- About
About - ADNI | Alzheimer's Disease Neuroimaging Initiative
- News & Publications
News & Publications - ADNI | Alzheimer's Disease...
- HELP / FAQ
HELP / FAQ - ADNI | Alzheimer's Disease Neuroimaging...
- About
All ADNI data are shared through the LONI Image and Data Archive (IDA), a secure research data repository. Interested scientists may obtain access to ADNI imaging, clinical, genomic, and biomarker data for the purposes of scientific investigation, teaching, or planning clinical research studies.
Samples, including genetic material, blood, and brain tissue collected from ADNI participants, are available for analyses, and the biospecimen requests are managed by the Resource Allocation Review Committee (RARC)s and the National Institute on Aging (NIA).
25 Ιουν 2018 · To download study data, click the "Download" section on the top bar and select "Study Data". This will bring you to a page that contains all of the important study data for ADNI. The most important sections are enrollment, demographics, study info, and imaging.
The ADNI study is made up of four distinct phases – ADNI1, ADNIGO, ADNI2, and ADNI3 – in each of which new participants were recruited while existing participants from earlier phases continued to be monitored. Our main dataset is the ADNI Merge dataset, from the Alzheimer’s Disease Neuroimaging Initiative.
12 Σεπ 2023 · We used conventional search methods to identify 1459 publications from 2021 to 2022 using ADNI data/samples and reviewed 291 impactful studies. This review details how ADNI studies improved disease progression understanding and clinical trial efficiency.
The Worldwide Alzheimer's Disease Neuroimaging Initiative (WW-ADNI) is a collaborative effort to investigate imaging and biofluid markers that can inform Alzheimer's disease treatment trials.
